Traws Pharma, Inc. Additional Paid in Capital, Common Stock
Traws Pharma, Inc. (TRAW) had Additional Paid in Capital, Common Stock of $651.69 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-14
- 2026-06-30: Additional Paid in Capital, Common Stock $651.69M.
- 2026-03-31: Additional Paid in Capital, Common Stock $641.68M.
- 2025-12-31: Additional Paid in Capital, Common Stock $639.26M.
- 2025-09-30: Additional Paid in Capital, Common Stock $637.01M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $651.69M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $641.68M 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $639.26M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $637.01M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $636.76M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $633.63M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $617.53M 10-K · filed 2026-04-15 | |
| 2024-09-30 | $617.20M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $505.02M 10-Q · filed 2024-08-15 | |
| 2024-03-31 | $493.45M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $493.32M 10-K · filed 2025-03-31 | $493.12M 10-K · filed 2024-04-01 |
| 2023-09-30 | $492.78M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $492.42M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $492.15M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $491.82M 10-K · filed 2024-04-01 | |
| 2022-09-30 | $491.49M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $491.18M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $490.94M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $490.64M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $490.42M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $470.33M 10-Q · filed 2021-08-16 | |
| 2021-03-31 | $468.06M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $434.59M 10-K · filed 2022-03-21 | $432.86M 10-K · filed 2021-03-18 |
| 2020-09-30 | $432.50M 10-Q · filed 2020-11-16 | |
| 2020-06-30 | $429.79M 10-Q · filed 2020-08-12 | |
| 2020-03-31 | $428.19M 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $413.88M 10-K · filed 2021-03-18 | |
| 2019-09-30 | $391.56M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $388.46M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $387.92M 10-Q · filed 2019-05-15 | |
| 2018-12-31 | $387.24M 10-K · filed 2020-03-27 | |
| 2018-09-30 | $387.06M 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $385.97M 10-Q · filed 2018-08-14 | |
| 2018-03-31 | $359.50M 10-Q · filed 2018-05-15 | |
| 2017-12-31 | $350.61M 10-K · filed 2019-04-01 | $350.51M 10-K · filed 2018-03-16 |
| 2017-09-30 | $349.10M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $348.67M 10-Q · filed 2017-08-14 | |
| 2017-03-31 | $342.98M 10-Q · filed 2017-05-15 | |
| 2016-12-31 | $342.48M 10-K · filed 2018-03-16 | |
| 2016-09-30 | $341.91M 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $332.39M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $331.53M 10-Q · filed 2016-05-11 | |
| 2015-12-31 | $328.56M 10-K · filed 2017-03-29 | $328.33M 10-K · filed 2016-03-28 |
| 2015-09-30 | $324.90M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $319.42M 10-Q · filed 2015-08-13 | |
| 2015-03-31 | $318.50M 10-Q · filed 2015-05-15 | |
| 2014-12-31 | $317.12M 10-K · filed 2016-03-28 | |
| 2014-09-30 | $316.27M 10-Q · filed 2014-11-14 | |
| 2014-06-30 | $314.63M 10-Q · filed 2014-08-14 | |
| 2014-03-31 | $313.27M 10-Q · filed 2014-05-15 | |
| 2013-12-31 | $311.09M 10-K · filed 2015-03-30 | |
| 2013-09-30 | $309.92M 10-Q · filed 2013-11-14 | |
| 2013-06-30 | $22.79M 10-Q · filed 2013-09-06 | |
| 2012-12-31 | $10.02M 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |